CuraCell completes CytoPLY™ named-patient publication series
CuraCell publishes third and final clinical report from CytoPLY™ named-patient program, demonstrating tumour responses across multiple difficult-to-treat solid tumours
News & Media
Recent Press Releases
CuraCell welcomes two new board members
CuraCell strengthens board of directors with appointment of Thomas Jaecklin and Martin Forster
CuraCell announces first patient included in clinical trial of innovative TIL therapy CC-38
First patient has been successfully included in the ongoing phase I/IIa clinical trial evaluating CuraCell’s autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, CC-38, for patients with metastatic colorectal and metastatic prostate cancer
CuraCell News and Media
Featured in Clinical Leader: CuraCell's Head of Clinical Operations, Torbjörn Ström, on rethinking the future of TIL therapy. (opens in a new window)
What if TIL therapy could be less burdensome for patients, more cost-efficient to produce, and effective against tumors that have traditionally been difficult to treat?
CuraCell featured by Labiotech among innovators redefining TIL for solid tumors (opens in a new window)
CuraCell is featured as one of the key innovators in Labiotech's article highlighting the growing momentum of tumor-infiltrating lymphocyte (TIL) therapy as a solution to solid tumors
CuraCell joins discussion on the future of SweTrial and clinical research in Sweden
CuraCell joined a KI Science Park panel discussion on SweTrial and boosting clinical trials in Sweden
CuraCell CEO shares perspective on the future of cell therapy
CuraCell CEO Jonas Båtelson shares his perspective on the rapidly evolving immuno-oncology landscape in a recent feature published by Citeline Industry Insights
CuraCell’s research on potent, tumour-targeted T cells
CuraCell’s research is focused on engineering highly potent, tumour-targeted T cells with improved activation and tumour-homing capabilities — helping immune cells infiltrate and function within the hostile solid-tumour microenvironment
BioStock highlights CuraCell's progress toward clinical development of TIL therapy
BioStock has featured CuraCell's latest scientific and clinical progress, highlighting the company's tumor-infiltrating lymphocyte (TIL) platform and its potential to address difficult-to-treat solid tumors
CuraCell supports prostate cancer awareness through Mustaschmilen
CuraCell participated in the Mustaschmilen Run, joining thousands of participants to raise awareness of prostate cancer and supporting efforts to improve outcomes for patients living with the disease
CuraCell study demonstrates long-term immune control achieved in prostate cancer
CuraCell is proud to announce the publication of its latest research article, “Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer”, in the peer-reviewed journal Frontiers in Oncology
CuraCell research publication highlights tumor regression driven by tumor-infiltrating lymphocytes in glioblastoma
CuraCell is proud to announce the acceptance of its latest research article, “Tumor-infiltrating lymphocytes-derived CD8⁺clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma”, in journal OncoImmunology
CuraCell receives CTA approval for phase I/IIa clinical trial with innovative TIL therapy CC-38
CuraCell today announced that the Paul-Ehrlich-Institut has approved the company’s Clinical Trial Application to initiate a phase I/IIa clinical trial evaluating its novel autologous Tumor-Infiltrating Lymphocyte therapy, CC-38
CuraCell partners with ScaleReady in cGMP manufacturing optimization
CuraCell signs collaboration agreement with ScaleReady under the G-REX Grant Program Initiative aimed to advance state of the art cell and gene-modified cell therapy development and manufacturing
CuraCell to present patient named clinical results at AACR and ISCT 2025 in the USA
CuraCell will present clinical outcomes of patients treated with our Tumor Infiltrating Lymphocytes-based therapy this spring at the AACR Annual Meeting and the ISCT Annual Meeting in the USA
CuraCell's CDMO partner Zellwerk-Berlin receives GMP licence
CuraCell’s manufacturing partner Zellwerk-Berlin GmBH, a specialized contract development & manufacturing organization, receives GMP authorization of its manufacturing site in Brandenburg, Germany
CuraCell holds final advice meeting with German regulator PEI
CuraCell today held its second advice meeting with the German regulator Paul-Erlich Institut
CuraCell selects IKF as CRO partner for its phase 1/2a trial
CuraCell has signed a partnership agreement with the German Clinical Research Organisation, IKF, located in Frankfurt, Germany
CuraCell signs collaboration agreement with Zellwerk-Berlin
CuraCell signs collaboration agreement with Zellwerk-Berlin, a Specialized Contract Development & Manufacturing Organization with engagements in Tumor Infiltrating Lymphocytes, Natural Killer cells and Mesenchymal Stromal Cells